Immune Microenvironment Articles & Analysis
7 news found
The enzyme DGKzeta is a lipid kinase that can down-modulate T-cell activation by catalyzing the conversion of diacylglycerol to phosphatidic acid, thus acting as a ligand-independent, intracellular immune checkpoint. An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumor antigens and has the potential to overcome multiple ...
ByBayer AG
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune ...
The results indicate superior tumor killing and persistence of CAR-NK cells as well as optimal activation of other anti-tumor immune cells. The authors' preclinical research illustrates the benefits of Senti Bio’s calibrated release gene circuit technology to improve CAR-NK cell functions aimed at enhancing solid tumor killing. ...
Louis (Abstract #1080870) during the Immunotherapy & Immune Microenvironment Session starting at 10:00 a.m. EST on November 12th. ...
” CTOS Meeting Abstract Title: SPEARHEAD-1: A Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (Abstract #1080870) Oral presentation: November 12, 2021, in the Immunotherapy & Immune Microenvironment Session starting at 10:00 a.m. EST. Presenter: Dr. ...
Exosomes are picking up steam among scientists because they can perform a role in the immune response, antigen presentation, cell migration, cell differentiation, and tumor invasion. Exosomes, which provide a mechanism for macromolecules to be exchanged between cells, play a part in the development of various illnesses, particularly in the modulation of the cancer ...
MOS is a revolutionary technology for immunotherapy development, which requires the patient’s immune microenvironment. Proceeds from the Series A funding will further advance Xilis’ proprietary MOS technology, expand its AI-driven capabilities, fund clinical studies for diagnostic development, and validate the use of MOS technology with biopharma ...